Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study.
about
Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled TrialsEfficacy of Adalimumab in Korean Patients with Crohn's Disease.Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)Metabolism of Anandamide by Human Cytochrome P450 2J2 in the Reconstituted System and Human Intestinal Microsomes.Is adalimumab protective in ischemia-reperfusion injury in lung?Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study.Balloon-Assisted Enteroscopy and Capsule Endoscopy in Suspected Small Bowel Crohn's DiseaseLong-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea.Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India
P2860
Q28070298-9086A782-98A1-40C9-9974-C81764D17987Q36658432-14D04973-94DD-4659-AADC-7F5DC7B69A54Q36848945-E43C2ED3-6DEF-4A6B-B722-B3DDCB6F9004Q36947747-DC9CDE6D-B4B0-4903-8222-46989FB9A3B7Q38600744-36EC3FD3-5166-42F0-8317-1B5A66700E6FQ38977012-E7BC1F73-CC8D-4604-B8B7-D133FF7E2D3FQ42377151-771A38AF-8631-4DBD-9ACB-580499BE68E8Q42699725-F27F9EC8-9CF8-4868-B8C1-8B51B65D43A5Q47932426-7DF35CB6-1CC5-4228-AB3F-F9F18D430D0AQ49821178-B5165BB7-BF35-43C9-8CA7-29D68C9D16B1Q50098797-D2866C67-A1FE-45A5-A997-981BC89D1663Q57284267-79B4BF97-0A8D-4711-A6E7-CC055E870921
P2860
Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety and Efficacy of Adalimu ...... y Bowel Disease (TSIBD) Study.
@ast
Safety and Efficacy of Adalimu ...... y Bowel Disease (TSIBD) Study.
@en
Safety and Efficacy of Adalimu ...... of Inflammatory Bowel Disease
@nl
type
label
Safety and Efficacy of Adalimu ...... y Bowel Disease (TSIBD) Study.
@ast
Safety and Efficacy of Adalimu ...... y Bowel Disease (TSIBD) Study.
@en
Safety and Efficacy of Adalimu ...... of Inflammatory Bowel Disease
@nl
prefLabel
Safety and Efficacy of Adalimu ...... y Bowel Disease (TSIBD) Study.
@ast
Safety and Efficacy of Adalimu ...... y Bowel Disease (TSIBD) Study.
@en
Safety and Efficacy of Adalimu ...... of Inflammatory Bowel Disease
@nl
P2093
P2860
P921
P356
P1433
P1476
Safety and Efficacy of Adalimu ...... y Bowel Disease (TSIBD) Study.
@en
P2093
Chen-Wang Chang
Cheng-Yi Wang
Chiao-Hsiung Chuang
Ching-Pin Lin
Deng Cheng Wu
Horng-Yuan Wang
Hsu-Heng Yen
Hung-Hsin Lin
Jau-Min Wong
Jen-Kou Lin
P2860
P304
P356
10.5217/IR.2014.12.4.287
P577
2014-10-27T00:00:00Z